Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) Shares Outstanding (Diluted Average) (2021 - 2025)

Medicinova (MNOV) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $49.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) changed N/A to $49.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $49.1 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $49.1 million at Medicinova, roughly flat from $49.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $49.1 million in Q4 2025, with the low at $48.6 million in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $49.0 million, with a median of $49.0 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Diluted Average) rose 0.5% in 2022, then changed 0.0% in 2023.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $48.6 million in 2021, then rose by 0.93% to $49.0 million in 2022, then changed by 0.0% to $49.0 million in 2023, then changed by 0.0% to $49.0 million in 2024, then rose by 0.04% to $49.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $49.1 million, $49.0 million, and $49.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.